Who We Are
Lantu is a global biotechnology company committed to advancing gene therapies for life-threatening
diseases. With a clear sense of urgency, we are leading a new era of drug development with a focus on
streamlining processes, reducing the time from drug discovery to patient treatment, and making
innovative therapies more accessible by lowering their cost. In partnership with leading gene therapy
CDMOs, medical teams, and healthcare professionals, we are building the most effective model for
transformative treatments.
Our mission is to redefine the future of medicine by efficiently delivering breakthrough gene therapies
that profoundly transform lives. We are committed to three
core principles:
Innovative Therapies
We focus on developing highly effective gene therapies for severe diseases,
with the aim of extending patient life expectancy and improving quality of life.
Challenging the Limits
We are dedicated to tackling the most difficult-to-treat conditions, such as
those that require therapies with large target genes or precise regulation of gene expression
and
function.
Affordability and Accessibility
We also want to be innovators that find creative and cost-effective solutions
to
make gene therapies widely accessible to all, including those living in low-to-middle income
countries.
2022
- World’s first gene therapy in clinical stage for Menkes disease
2024
- Gene therapy in clinical stage for SMA
- Gene therapy in clinical stage for beta-thalassemia
2025
- World’s first gene therapy pipeline licensed out to mid-to-low income country
2026
- The story is not over yet, the excitement continues
